Aarti Drugs Ltd

524348 Momentum

Summary

Fair Value Assessment
Momentum
Undervalued (19% Discount)
Fair ValueQ604.89UncertaintyHigh
Close Price487.35Jul 04, 2025
Market Closed
487.35
Price Up by 3.50 | 0.72 %
Previous Close
487.35
Day Range
478.50 – 497.50
Year Range
312.50 – 634.90
Bid / Ask
Market Cap
44.5 Bil
Volume / Average
25.0 k / 34.6 k
Beta (5-Year)
Shares Outstanding
91.27 Mil
Primary Exchange
Bombay Stock Exchange

Business Description
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
Contact
Road No. 29, Plot Number 109-D Mahendra Industrial Estate, Ground Floor, Mumbai, MH 400022
T +91 2224019025
www.aartidrugs.co.in opens in a new tab
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Mar 31, 2025
Fiscal Year End
Mar 31, 2025
Employees
2,766

Key Metrics

Key-Metrics - Financial Summary shows the income statement, balance sheet , cash flow statement data - 5 year and 10 year of the company stock.
Income Statement (in Bil, except ratios)
03/31/2025
03/2025
03/2024
03/2023
03/2022
03/2021
Revenue
23.87 23.87 25.09 27.16 24.89 21.55
Revenue Growth %
-5.60% -5.60% -7.27% 9.14% 15.49% 19.31%
Gross Profit
8.45 8.45 4.85 4.93 5.04 6.00
Gross Profit Margin %
35.40% 35.40% 19.33% 18.17% 20.24% 27.86%
Operating Income
2.31 2.31 2.78 2.68 2.98 3.95
Operating Margin %
9.69% 9.69% 11.07% 9.86% 11.97% 18.33%
EBIT
2.48 2.48 2.67 2.57 2.90 3.89
EBIT Margin %
10.37% 10.37% 10.62% 9.45% 11.65% 18.07%
EBITDA
3.03 3.03 3.18 3.07 3.40 4.39
EBITDA Margin %
12.71% 12.71% 12.67% 11.31% 13.66% 20.39%
Net Income
1.68 1.68 1.71 1.66 2.05 2.80
Net Profit Margin %
7.04% 7.04% 6.84% 6.13% 8.24% 13.01%
Basic EPS
18.35 18.35 18.56 17.96 22.12 30.09
Diluted EPS
18.35 18.35 18.56 17.96 22.12 30.09
Normalized EPS
17.25 17.25 18.50 17.85 22.21 30.13
Total Dividends per Share
1.00 1.00 1.00 1.00 1.00 2.50
Key-Metrics - Financial Summary shows the income statement, balance sheet , cash flow statement data - 5 year and 10 year of the company stock.
Balance Sheet (in Bil, except ratios)
03/31/2025
03/2025
03/2024
03/2023
03/2022
03/2021
Total Assets
25.75 25.75 24.32 24.21 22.08 17.66
Total Liabilities
12.05 12.05 11.50 12.29 11.72 8.53
Total Debt
6.15 6.15 5.64 6.09 5.43 3.51
Total Equity
13.69 13.69 12.82 11.93 10.36 9.13
Cash And Cash Equivalents
0.05 0.05 0.07 0.08 0.22 0.09
Working Capital
5.01 5.01 5.25 5.59 4.53 4.61
Shares Outstanding (Mil)
92.60 92.60
Book Value Per Share
149.99 149.99 139.40 128.77 111.92 98.01
Total Debt To Equity
0.45 0.45 0.44 0.51 0.52 0.38
Key-Metrics - Financial Summary shows the income statement, balance sheet , cash flow statement data - 5 year and 10 year of the company stock.
Cash Flow Statement (in Bil, except ratios)
03/31/2025
03/2024
03/2023
03/2022
03/2021
03/2020
Cash From Operating Activities
2.45 3.59 1.34 0.70 1.55 2.51
Cash From Investing Activities
-1.65 -2.24 -1.64 -1.49 -0.72 -0.33
Cash From Financing Activities
-0.82 -1.36 0.17 0.92 -0.81 -2.15
Capital Expenditures
1.77 2.26 1.65 1.52 0.88 0.48
Free Cash Flow
0.30 -0.02 0.49 0.84 2.30 1.50
Change in Cash
-0.02 -0.01 -0.13 0.13 0.02 0.02

Profile

Executives shows executive data in a table format includes information on Key Executives, Board of Directors.
Name (Age)
5-Year Trend
2021
2022
2023
2024
2025
Prakash Moreshwar Patil (—) Chairman of the Board, Chief Executive Officer and Managing Director
Rashesh Chandrakant Gogri (—) Director and Managing Director
Harshit Manilal Savla (—) Director and Joint Managing Director
Total Compensation for all Key Executives
Transaction History

Shares in Thousands
0 5 10 15 20 25 30 35 40
>
Oops!
Something went wrong.
Sep
2023
    • Buy
    • Acquisition
    • Option Exercise
    • Disposition
    • Sell
Transaction Detail
Oops!
Something went wrong.

Ownership

Ownership lists the Fund owners and Intitutional owners of the stock.
Name
Morningstar
Rating
% Total
Shares Held
% Total
Assets
Trend
Prev. 8 Qtrs
Current Shares
Change Amount
Change %
Date
DSP Small Cap Reg Gr 6.97 1.73 6,359,826
487,686
8.31%
May 31, 2025
ICICI Pru Pharma Healthcare Diag Gr Not Rated 1.74 1.28 1,589,896
180,623
12.82%
May 31, 2025
DSP Healthcare Fund Reg Gr Not Rated 0.93 1.28 852,155
0
0.00%
May 31, 2025
DFA Emerging Markets Core Equity 2 I 0.27 0.00 250,368
0
0.00%
May 31, 2025
Motilal Oswal Nifty Mcrcp 250 Idx Reg Gr Not Rated 0.12 0.20 108,875
6,361
6.21%
May 31, 2025
Total (for Top 5) 10.04 9,161,120
674,670

© Copyright 2025 Morningstar, Inc. All rights reserved.
Terms of Use    Privacy Policy
© Copyright 2025 Morningstar, Inc. All rights reserved. Please read our Terms of Use above. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
As of December 1st, 2023, the ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
Company: Morningstar India Private Limited; Regd. Office: 9th floor, Platinum Technopark, Plot No. 17/18, Sector 30A, Vashi, Navi Mumbai – 400705, Maharashtra, India; CIN: U72300MH2004PTC245103; Telephone No.: +91-22-61217100; Fax No.: +91-22-61217200; Contact: Morningstar India Help Desk (e-mail: helpdesk.in@morningstar.com) in case of queries or grievances.
Top